US OK’s first-in-class drug Aimovig for migraine prevention
Amgen and Novartis’ Aimovig has become the first anti-CGRP therapy to win regulatory clearance in the US, winning approval for migraine prevention.
Read More
Tag: CGRP-R
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
